Cancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
Adv Exp Med Biol. 2022;1367:411-431. doi: 10.1007/978-3-030-92616-8_17.
Adverse drug reactions (ADRs) are the cause of nearly three to six percent of inpatient admissions and are associated with high morbidity and mortality rates. Cutaneous adverse drug reactions (cADRs) represent the most frequent ADRs observed among patients during hospital stay. Recent investigations have found that various HLA genotypes have a significant association with ADRs, especially immune-mediated ADRs. This chapter is devoted to the description of the immunopathogenic mechanism of these reactions and the specific HLA-drug associations. Also, we discuss the association of other non-HLA genes with the development of cADRs and provide a summary of the currently approved recommendations on pre-treatment HLA genotyping tests.
药物不良反应（ADR）是近 3%至 6%住院患者的病因，与高发病率和死亡率相关。皮肤药物不良反应（cADR）是住院期间患者最常见的药物不良反应。最近的研究发现，各种 HLA 基因型与 ADR ，特别是免疫介导的 ADR 显著相关。本章致力于描述这些反应的免疫发病机制以及特定的 HLA-药物相关性。此外，我们还讨论了其他非 HLA 基因与 cADR 发展的相关性，并对目前批准的 HLA 基因分型检测预处理建议进行了总结。
